Fibrous tumor (solitary fibrous tumor) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that originates from fibroblastic cells, most often arising in the pleura (the lining of the lungs) but can occur anywhere in the body—including the abdomen, head and neck, meninges, and extremities. Historically described as a “benign” pleural tumor, advances in pathology have shown that SFTs exist on a spectrum from completely benign to malignant, and the majority are now classified as intermediate‑grade lesions.

• Incidence: Approximately 2–3 cases per million people per year in the United States <sup>1</sup>.
• Age: Most commonly diagnosed in adults aged 40–70 years, though pediatric cases are reported.
• Sex: Slight male predominance (≈55% male) but overall distribution is fairly equal.
• Geography: No clear regional differences; cases are reported worldwide.

Because SFTs can be asymptomatic and grow slowly, they are often discovered incidentally on imaging performed for unrelated reasons.

Symptoms

Symptoms depend on the tumor’s size, location, and whether it is producing hormones (rarely). Below is a comprehensive list:

General / Systemic

• Fatigue – often due to anemia caused by chronic blood loss or the rare Doege‑Pettersson syndrome (paraneoplastic hypoglycemia).
• Weight loss – unexplained loss may signal a larger or more aggressive tumor.
• Fever or night sweats – uncommon but can occur with malignant transformation.

Respiratory (when the tumor is pleural or thoracic)

• Persistent cough
• Shortness of breath (dyspnea) especially when the mass compresses lung tissue
• Chest pain or tightness
• Recurrent pneumothorax (collapsed lung) – reported in ~5% of pleural SFTs <sup>2</sup>.

Abdominal / Pelvic

• Abdominal fullness or a palpable mass
• Early satiety, nausea, or vomiting if the tumor presses on the stomach or intestines
• Hematuria or flank pain when originating in the kidney or ureter.

Neurologic (when meningeal or skull‑base)

• Headache, visual changes, or cranial nerve palsies
• Seizures (rare)

Paraneoplastic (rare)

• Hypoglycemia: Tumor secretes insulin‑like growth factor‑2 (IGF‑2). Patients may feel jittery, sweaty, or confused.
• Hypertension or Raynaud phenomenon: Occasionally reported due to secreted vasoactive substances.

Causes and Risk Factors

The exact cause of solitary fibrous tumor is unknown. Current research points to a genetic driver:

• NAB2‑STAT6 gene fusion: A chromosomal inversion that creates a fusion protein, detectable by immunohistochemistry (STAT6 nuclear positivity). This alteration is present in >90% of SFTs and is considered pathogenic <sup>3</sup>.

Risk Factors

• Age: Incidence rises after age 40.
• Previous radiation exposure: Cases reported after therapeutic radiation, although causality isn’t firmly established.
• Occupational exposure to asbestos: Linked to pleural tumors, but evidence specific to SFT is limited.
• Genetic predisposition: No hereditary syndrome has been definitively linked, but rare familial cases suggest a possible inherited susceptibility.

Diagnosis

Diagnosis is a stepwise process that combines imaging, histopathology, and molecular testing.

Imaging Studies

• Chest X‑ray: May reveal a solitary, well‑defined mass.
• Computed Tomography (CT): Preferred for thoracic, abdominal, and pelvic lesions. Typical features include a soft‑tissue density mass with possible calcifications and heterogeneous enhancement after contrast.
• Magnetic Resonance Imaging (MRI): Useful for spinal, meningeal, or musculoskeletal SFTs. Shows iso‑ to hypointense signal on T1, variable T2, and strong contrast enhancement.
• Positron Emission Tomography (PET‑CT): Helps assess metabolic activity and detect metastasis; higher SUV values correlate with malignant potential.

Biopsy & Histopathology

1. Core needle or excisional biopsy: Obtains tissue for definitive diagnosis.
2. Microscopic findings: Spindle‑shaped cells in a “patternless” storiform arrangement, hemangiopericytoma‑like branching vessels, and variable collagen deposition.
3. Immunohistochemistry (IHC):
   • STAT6 nuclear staining – highly sensitive and specific.
   • CD34 positive in ~90% of cases.
   • Negative for cytokeratins, S‑100, and desmin (helps differentiate from other spindle‑cell tumors).
4. Molecular testing: PCR or next‑generation sequencing confirms NAB2‑STAT6 fusion, especially when IHC is equivocal.

Risk Stratification

Pathologists use a risk model (e.g., Demicco et al.) that incorporates:

• Patient age
• Tumor size
• Mitotic count (per 10 high‑power fields)
• Presence of necrosis

The model predicts the likelihood of metastasis and guides follow‑up intensity.

Treatment Options

Treatment is individualized based on tumor location, size, histologic grade, and patient comorbidities.

Surgical Management

• Complete surgical excision with negative margins (R0 resection): Gold standard for both benign and low‑grade malignant SFTs. Recurrence rates drop from 30% to <10% when margins are clear.
• Laparoscopic or video‑assisted thoracoscopic surgery (VATS): Minimally invasive options for appropriately sized thoracic lesions.
• En‑bloc resection of involved structures: May be required for large or invasive tumors (e.g., chest wall, diaphragm).

Radiation Therapy

• Considered for inoperable, recurrent, or partially resected tumors.
• Typical dose: 50–60 Gy in 25–30 fractions.
• Evidence (retrospective series) shows local control rates of 70–80% <sup>4</sup>.

Systemic Therapies

There is no standard chemotherapy, but several agents have shown activity in advanced or metastatic disease:

• Anthracycline‑based regimens (e.g., doxorubicin + ifosfamide): Response rates ~20%.
• Tyrosine‑kinase inhibitors (TKIs):
  • Trabectedin – FDA‑approved for soft‑tissue sarcoma; modest activity in SFT.
  • Sunitinib or Pazopanib – Target VEGF pathways; partial responses reported.
• Anti‑IGF‑2 therapy: For hypoglycemia‑producing tumors, glucocorticoids or somatostatin analogs (e.g., octreotide) can control symptoms.

Follow‑Up & Surveillance

Even after complete resection, lifelong surveillance is recommended because late recurrence (up to 15 years) can occur.

• CT or MRI every 6–12 months for the first 5 years.
• Annual imaging thereafter.

Lifestyle & Supportive Measures

• Maintain a balanced diet rich in fruits, vegetables, and lean protein to support healing.
• Engage in regular, moderate exercise (as tolerated) to improve cardiopulmonary reserve.
• Avoid tobacco and limit alcohol, especially after thoracic surgery.

Living with Fibrous Tumor (Solitary Fibrous Tumor)

Adapting to life after diagnosis involves physical, emotional, and practical steps.

Physical Health

• Post‑operative care: Follow wound‑care instructions, perform deep‑breathing exercises, and attend physiotherapy if chest surgery was performed.
• Monitor for hypoglycemia: Keep a glucometer handy if you have Doege‑Pettersson syndrome; treat with quick‑acting carbs and discuss medication adjustments with your endocrinologist.
• Vaccinations: Stay up‑to‑date on flu and pneumococcal vaccines, especially after thoracic surgery.

Emotional Well‑Being

• Join support groups (e.g., Sarcoma Support Groups, rare‑tumor forums).
• Consider counseling or psychotherapy to address anxiety about recurrence.

Practical Tips

• Keep a personal health record with pathology reports, imaging, and dates of follow‑up.
• Use medical alert jewelry if you have a history of hypoglycemia.
• Plan ahead for work or school—most patients return to normal activities within 4–6 weeks after uncomplicated surgery.

Prevention

Because SFT development is largely sporadic and linked to a specific genetic mutation, primary prevention is limited. However, you can reduce overall cancer risk and potentially lower secondary factors:

• Avoid unnecessary radiation exposure; discuss risks of diagnostic CT scans with physicians.
• Minimize exposure to known thoracic irritants (asbestos, silica).
• Maintain a healthy weight and exercise regularly—while not directly preventing SFT, these habits improve overall resilience.

Complications

Complications differ by tumor location and behavior.

• Local recurrence: 10–30% depending on margin status; may require repeat surgery or radiotherapy.
• Metastasis: Occurs in 5–20% of cases, most commonly to lungs, liver, bone, and brain. Median time to metastasis ~4–5 years.
• Paraneoplastic hypoglycemia: Can cause seizures or loss of consciousness if untreated.
• Post‑operative complications: Pneumothorax, infection, or chronic pain after chest wall resection.
• Organ dysfunction: Large intra‑abdominal SFTs may cause bowel obstruction or renal impairment.

When to Seek Emergency Care

---

References:

1. National Cancer Institute. “Solitary Fibrous Tumor of the Pleura.” SEER Cancer Statistics, 2023.
2. Huang Q et al. “Pneumothorax associated with solitary fibrous tumors of the pleura.” Ann Thorac Surg. 2021;112(3):1025‑1031.
3. Robinson DR et al. “Identification of the NAB2‑STAT6 fusion gene in solitary fibrous tumor.” Nat Genet. 2013;45(2):180‑185.
4. Stacchiotti S et al. “Radiotherapy for solitary fibrous tumor: a systematic review.” Radiother Oncol. 2022;165:109‑119.

For personalized advice, always consult your primary care physician, oncologist, or a specialized sarcoma center.

```